# Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

> **NCT05690048** · PHASE2 · RECRUITING · sponsor: **Michael Dill** · enrollment: 48 (estimated)

## Conditions studied

- Immunotherapy
- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** Fecal microbiota transfer
- **DRUG:** Vancomycin Oral Capsule
- **DRUG:** Atezolizumab + Bevacizumab
- **DRUG:** Placebo Vancomycin Oral Capsule
- **DRUG:** Placebo Fecal microbiota transfer

## Key facts

- **NCT ID:** NCT05690048
- **Lead sponsor:** Michael Dill
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-16
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-08-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05690048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05690048, "Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05690048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*